生物活性

• 描述Isoquercitrin is an effective antioxidant and an eosinophilic inflammation suppressor. Isoquercitrin reduced the depletion of glutathione (GSH) caused by elevation of specific radical species (H(2)O(2), OH* and O(2)(*-)) in RGC-5 cells in culture and blunted the decrease in catalase and glutathione peroxidase 1 (Gpx-1) caused by exposure of RGC-5 cells to H(2)O(2). Furthermore, isoquercitrin potently attenuated the lipid peroxidation of rat brain homogenates initiated by nitric oxide, with an IC(50) value of 1.04 μM^[3]. Isoquercitrin (20 mg/kg/day) treatment achieved significantly higher SFI and higher amplitude of CMAP, promoted the nerve regeneration and remyelination, increased the production of GAP43, NF200, MAG and PMP22, alleviated target muscle atrophy and autophagy, and suppressed the expression of ATG7, PINK1 and Beclin1 in soleus muscles after sciatic nerve crush. The administration of isoquercitrin at 40 and 320 µM showed a dose dependent, and high doses of isoquercitrin (160 and 320 µM) showed better performance in promoting axonal regeneration of DRGs neurons, and the proliferation and migration of Schwann cells than low dose of isoquercitrin (40 µM)^[4]. The cell proliferation of osteoblasts and BMSCs was promoted by isoquercitrin at low concentrations. High concentrations of isoquercitrin promoted the osteogenic differentiation via RUNX2 expression in osteoblasts and via the bone morphogenetic protein (BMP) pathway in BMSCs^[5]. Quercetin and isoquercitrin inhibit gluconeogenesis in hepatocytes, which may be related to the LKB1 upregulation and phosphorylation of AMPKα^[6].
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT01691404	Hypertension ... more >>Endothelial Dysfunction Collapse <<	Not Applicable	Completed	-	Netherlands ... more >> Wageningen University Wageningen, Netherlands, 6703 HD Collapse <<
  NCT02195232	Thromboembolism of Vein VTE in... more >> Colorectal Cancer Thromboembolism of Vein in Pancreatic Cancer Thromboembolism of Vein in Non-small Cell Lung Cancer Collapse <<	Phase 2 Phase 3	Recruiting	April 2023	United States, California ... more >> USC/Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Howard Liebman, MD    323-865-0579    Liebman_h@med.usc.edu    Principal Investigator: Howard Liebman, MD          VA Northern California Health Care System Recruiting Sacramento, California, United States, 95655 Contact: Theodore Wun, MD    916-734-1507    Twun@ucdavis.edu    Principal Investigator: Theodore Wun, MD          United States, Connecticut VA Connecticut Healthcare System Recruiting West Haven, Connecticut, United States, 06450 Contact: Ellice Wong, MD    203-937-3421    Ellice.wong@va.gov    Principal Investigator: Ellice Wong, MD          United States, District of Columbia Veterans Affair Medical Center Recruiting Washington, District of Columbia, United States, 20422 Contact: Anita Aggarwal, DO, PhD    202-745-8000    anita.aggarwal@va.gov    Principal Investigator: Anita Aggarwal, DO, PhD          United States, Maine York Hospital-Oncology Treatment Center Recruiting York, Maine, United States, 03909 Contact: Marilyn D. McLaughlin, MD    207-351-3777    Mmclaughlin@yorkhospital.com    Principal Investigator: Marilyn D. McLaughlin, MD          United States, Massachusetts Boston VA Healthcare System Recruiting Boston, Massachusetts, United States, 02130 Contact: Kenneth Bauer, MD    857-364-5033    kenneth.bauer@va.gov    Principal Investigator: Kenneth A. Bauer, MD          Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Jeffrey Zwicker, MD    617-667-9299    jzwicker@bidmc.harvard.edu    Principal Investigator: Jeffrey Zwicker, MD          Mount Auburn Hospital Recruiting Waltham, Massachusetts, United States, 02138 Contact: Thomas Caughey, MD    617-497-9646    tcaughey@mah.harvard.edu    Principal Investigator: Thomas Caughey, MD          United States, Missouri Washington University in St. Louis Recruiting Saint Louis, Missouri, United States, 63110 Contact: Kristen Sanfilippo, MD    314-362-0233    ksanfilippo@wustl.edu    Principal Investigator: Kristen Sanfilippo, MD          United States, Rhode Island Providence VA Medical Center Recruiting Providence, Rhode Island, United States, 02908 Contact: Katherine Faricy-Anderson, MD    401-732-7100 ext 6158    Katherine.faricy-anderson@va.gov    Principal Investigator: Katherine Faricy-Anderson, MD          United States, Vermont White River Junction VA Medical Center Recruiting White River Junction, Vermont, United States, 05009 Contact: Nancy Kuemmerle, DO, PhD    802-295-9363    Nancy.Kuemmerle@va.gov    Principal Investigator: Nancy Kuemmerle, DO, PhD Collapse <<
  NCT02818699	Overweight Ob... more >>ese Collapse <<	Not Applicable	Recruiting	January 2018	United States, Massachusetts ... more >> Human Nutrition Research Center on Aging at Tufts University Recruiting Boston, Massachusetts, United States, 02111 Collapse <<

• 参考文献

• [1] Chen Q, Li P, et al. Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen-activated protein kinase signalling pathway. Oncol Rep. 2015 Feb;33(2):840-8.

  [2] Wang X, Schroder HC, et al. Isoquercitrin and polyphosphate co-enhance mineralization of human osteoblast-like SaOS-2 cells via separate activation of two RUNX2 cofactors AFT6 and Ets1. Biochem Pharmacol. 2014 Jun 1;89(3):413-21.

  [3] Jung SH, Kim BJ, Lee EH, Osborne NN. Isoquercitrin is the most effective antioxidant in the plant Thuja orientalis and able to counteract oxidative-induced damage to a transformed cell line (RGC-5 cells). Neurochem Int. 2010 Dec;57(7):713-21

  [4] Qiu J, Yang X, Wang L, Zhang Q, Ma W, Huang Z, Bao Y, Zhong L, Sun H, Ding F. Isoquercitrin promotes peripheral nerve regeneration through inhibiting oxidative stress following sciatic crush injury in mice. Ann Transl Med. 2019 Nov;7(22):680

  [5] Li M, Zhang C, Li X, Lv Z, Chen Y, Zhao J. Isoquercitrin promotes the osteogenic differentiation of osteoblasts and BMSCs via the RUNX2 or BMP pathway. Connect Tissue Res. 2019 Mar;60(2):189-199

  [6] Chen L, Shen T, Zhang CP, Xu BL, Qiu YY, Xie XY, Wang Q, Lei T. Quercetin and Isoquercitrin Inhibiting Hepatic Gluconeogenesis Through LKB1-AMPKα Pathway. Acta Endocrinol (Buchar). 2020 Jan-Mar;16(1):9-14

• 更多

• Collapse